Walgreens (NYSE: WAG) (Nasdaq: WAG) had October sales of $6.80 billion,
an increase of 6.9 percent from $6.36 billion for the same month in
fiscal 2014.
Total front-end sales increased 2.7 percent in October compared with the
same month in fiscal 2014, while comparable store front-end sales
increased 2.0 percent. Customer traffic in comparable stores decreased
1.9 percent while basket size increased 3.9 percent.
Prescriptions filled at comparable stores increased by 3.6 percent in
October and increased 4.1 percent on a calendar day-shift adjusted
basis. October 2014 had one additional Friday and one fewer Tuesday
compared with October 2013. These calendar shifts negatively impacted
prescriptions filled at comparable stores by 0.5 percentage point.
Prescriptions filled at comparable stores were positively impacted by
0.7 percentage point due to more flu shots versus last year.
October pharmacy sales increased by 9.9 percent. Comparable store
pharmacy sales increased 7.5 percent and increased by a calendar
day-shift adjusted 8.0 percent. Calendar day shifts negatively impacted
pharmacy sales in comparable stores by 0.5 percentage point. Calendar
day-shift adjusted comparable store pharmacy sales were negatively
impacted by 1.9 percentage points due to generic drug introductions in
the last 12 months, and were positively impacted by 0.4 percentage point
due to more flu shots versus last year. Pharmacy sales accounted for
67.3 percent of total sales for the month.
Flu shots administered at pharmacies and clinics season to date were
more than 5.7 million versus approximately 4.9 million last year.
Sales in comparable stores increased by 5.6 percent in October. Calendar
day shifts negatively impacted total comparable sales by 0.3 percentage
point, while more flu shots versus last year positively impacted total
comparable sales by 0.3 percentage point. Generic drug introductions in
the last 12 months negatively impacted total comparable sales by 1.3
percentage points.
Calendar 2014 year-to-date sales for the first 10 months were $64.15
billion, an increase of 6.1 percent from $60.47 billion in 2013.
Fiscal 2015 year-to-date sales for the first two months were $13.22
billion, up 7.7 percent from $12.28 billion in the comparable period in
fiscal 2014.
Walgreens opened 16 stores during October, including four relocations,
and closed one.
On Oct. 31, Walgreens operated 8,319 locations with a presence in all 50
states, the District of Columbia, Puerto Rico and the U.S. Virgin
Islands. That includes 8,218 drugstores, 87 more than a year ago,
including 70 net stores acquired over the last 12 months. The company
also operates infusion and respiratory services facilities, specialty
pharmacies and mail service facilities. Walgreens digital business
includes Walgreens.com, drugstore.com, Beauty.com, SkinStore.com and
VisionDirect.com. Walgreens also manages more than 400 Healthcare Clinic
and provider practice locations around the country.
October Comparable Sales and Prescriptions Filled
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Calendar
|
|
|
|
Cough,
|
|
|
|
Flu
|
|
|
|
|
|
|
|
|
|
|
|
|
Shift
|
|
|
|
Cold, Flu
|
|
|
|
Shot
|
|
|
|
Generics
|
|
|
|
|
Actual
|
|
|
|
Impact
|
|
|
|
Impact
|
|
|
|
Impact
|
|
|
|
Impact
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comp Sales
|
|
|
|
5.6%
|
|
|
|
-0.3%
|
|
|
|
-0.1%
|
|
|
|
0.3%
|
|
|
|
- 1.3%
|
Comp Front End
|
|
|
|
2.0%
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
Comp Rx Sales
|
|
|
|
7.5%
|
|
|
|
-0.5%
|
|
|
|
-0.1%
|
|
|
|
0.4%
|
|
|
|
- 1.9%
|
Comp Rx Scripts
|
|
|
|
3.6%*
|
|
|
|
-0.5%
|
|
|
|
-0.1%
|
|
|
|
0.7%
|
|
|
|
-
|
* Includes +1.1 percentage points from patients filling more 90-day
prescriptions
Please note: Sales numbers and the adjustments shown in the table are
preliminary, unaudited and subject to revision. Comparable stores are
defined as those drugstore locations open for at least 12 consecutive
months without closure for seven or more consecutive days and without a
major remodel or a natural disaster in the past 12 months. Acquired
operating locations and relocations are not included as comparable
stores for the first 12 months after the acquisition or relocation.
Cautionary Note Regarding Forward-Looking Statements: Statements
in this release that are not historical are forward-looking statements
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Words such as "expect," “likely,”
"outlook," “forecast,” "would," "could," "should," “can,” “will,”
"project," "intend," "plan," "goal,” “target,” “continue," "sustain,"
“synergy,” "on track," "believe," "seek," "estimate," "anticipate,"
"may," “possible,” "assume," and variations of such words and similar
expressions are intended to identify such forward-looking statements.
These forward-looking statements are not guarantees of future
performance and involve risks, assumptions and uncertainties, including,
but not limited to, those described in Item 1A (Risk Factors) of our
most recent Annual Report on Form 10-K, as amended, which is
incorporated herein by reference, and in other documents that we file or
furnish with the Securities and Exchange Commission. Should one or more
of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from
those indicated or anticipated by such forward-looking statements.
Accordingly, you are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they are
made. Except to the extent required by law, Walgreens does not
undertake, and expressly disclaims, any duty or obligation to update
publicly any forward-looking statement after the date of this release,
whether as a result of new information, future events, changes in
assumptions or otherwise.
Copyright Business Wire 2014